bosutinib 400 MG Oral Tablet [Bosulif]
- RxCUI
- 1987734
- RxNorm name
- bosutinib 400 MG Oral Tablet [Bosulif]
- Display name
- BOSULIF (Oral Pill)
- Full name
- bosutinib 400 MG Oral Tablet [Bosulif]
- Term type
- SBD
- Status
- Active
- Strength
- 400 mg
- Dose form
- Tab
- Route
- Oral Pill
- Updated
- 2026-11-02 22:16:58
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 122017
- Active start
- 122017
- Multiple ingredient
- NO
- Branded
- YES
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| bosutinib | 400 MG / 1 EACH | bosutinib | bosutinib |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Oral Tablet | 317541 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| bosutinib | 1307619 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | Bosulif 400 MG Oral Tablet | 1 | NAMES |
| RxNorm Name | bosutinib 400 MG Oral Tablet [Bosulif] | 1 | NAMES |
| RxNorm Synonym | 2 | NAMES | |
| TTY | SBD | 1 | ATTRIBUTES |
| SPL_SET_ID | 2 | CODES | |
| RxCUI | 1987734 | 1 | CODES |
| MMSL_CODE | BD32442 | 1 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 0069-0193-01 | 0069-0193 | BOSULIF Bosutinib | Pfizer Laboratories Div Pfizer Inc | NDA203341 |
| 63539-193-30 | 63539-193 | BOSULIF Bosutinib | U.S. Pharmaceuticals | NDA203341 |
Drugs@FDA Applications#
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BOSULIF | BOSUTINIB | U.S. Pharmaceuticals | d5929f91-6496-4c0e-97e8-0bd524e15763 | 2026-05-28 | Warnings, Adverse reactions | 63539-193-30 63539-193 63539019330 1987734 |
| BOSULIF | BOSUTINIB | Pfizer Laboratories Div Pfizer Inc | adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | 2026-03-10 | Warnings, Adverse reactions | 0069-0193-01 0069-0193 00069019301 1987734 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | Bosulif 400 MG Oral Tablet [PSN] · bosutinib 400 MG Oral Tablet [Bosulif] [SBD] · Bosulif 400 MG (as bosutinib monohydrate 413.6 MG) Oral Tablet [SY] · Bosulif 400 MG Oral Tablet [SY] | 4 | 32 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260310 |
| d5929f91-6496-4c0e-97e8-0bd524e15763 | Bosulif 400 MG Oral Tablet [PSN] · bosutinib 400 MG Oral Tablet [Bosulif] [SBD] · Bosulif 400 MG (as bosutinib monohydrate 413.6 MG) Oral Tablet [SY] · Bosulif 400 MG Oral Tablet [SY] | 4 | 6 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260528 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| d5929f91-6496-4c0e-97e8-0bd524e15763 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | U.S. Pharmaceuticals | Pfizer Manufacturing Deutschland GmbH | Pfizer Ireland Pharmaceuticals Unlimited Company | 20260528 |
| d5929f91-6496-4c0e-97e8-0bd524e15763 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | U.S. Pharmaceuticals | Pfizer Manufacturing Deutschland GmbH | Pfizer Ireland Pharmaceuticals Unlimited Company | 20260318 |
| adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | Pfizer Laboratories Div Pfizer Inc | Pfizer Manufacturing Deutschland GmbH | Pfizer Ireland Pharmaceuticals Unlimited Company | 20260310 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | L01EA | BCR-ABL tyrosine kinase inhibitors | ATC1-4 | bosutinib | |
| FDASPL | N0000175605 | Kinase Inhibitor | EPC | has_epc | bosutinib |
| FDASPL | N0000020009 | Bcr-Abl Tyrosine Kinase Inhibitors | MOA | has_moa | bosutinib |
| MEDRT | D000814 | Aniline Compounds | CHEM | has_ingredient | bosutinib |
| MEDRT | D009570 | Nitriles | CHEM | has_ingredient | bosutinib |
| MEDRT | D011804 | Quinolines | CHEM | has_ingredient | bosutinib |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | bosutinib |
| MEDRT | D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | DISEASE | may_treat | bosutinib |
| MEDRT | N0000020001 | Tyrosine Kinase Inhibitors | MOA | has_moa | bosutinib |
| MEDRT | N0000175672 | Cellular Proliferation Alteration | PE | has_pe | bosutinib |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 400 MG |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| CODES | NDA | NDA203341 |
| NAMES | Prescribable Synonym | Bosulif 400 MG Oral Tablet |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |